Erlotinib
BO20571
Phase 2 small_molecule completed
Quick answer
Erlotinib for Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed